Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Short term Debt (2020 - 2025)

Historic Short term Debt for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.1 million.

  • Insight Molecular Diagnostics' Short term Debt rose 7198.7% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 7198.7%. This contributed to the annual value of $228000.0 for FY2024, which is 9014.69% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Short term Debt is $1.1 million, which was up 7198.7% from $689000.0 recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Short term Debt peaked at $11.7 million during Q2 2021, and registered a low of $109000.0 during Q3 2022.
  • Its 5-year average for Short term Debt is $1.6 million, with a median of $689000.0 in 2025.
  • Its Short term Debt has fluctuated over the past 5 years, first tumbled by 9512.52% in 2022, then skyrocketed by 202293.58% in 2023.
  • Insight Molecular Diagnostics' Short term Debt (Quarter) stood at $1.4 million in 2021, then tumbled by 92.15% to $109000.0 in 2022, then soared by 2022.94% to $2.3 million in 2023, then crashed by 90.15% to $228000.0 in 2024, then skyrocketed by 363.16% to $1.1 million in 2025.
  • Its Short term Debt stands at $1.1 million for Q3 2025, versus $689000.0 for Q2 2025 and $433000.0 for Q1 2025.